Catalog No.
Product Name
Application
Product Information
Citations
-
LCL-PEG3-N3 (hydrochloride) Decoy Oligonucleotide Ligand
LCL-PEG3-N3 hydrochloride is a decoy oligonucleotide ligand targeting E3 ligases, facilitating the development of chimeric molecules such as LCL-ER(dec) for the degradation of estrogen receptors. This compound features an azide functional group, allowing it to participate in copper-catalyzed azide-alkyne cycloaddition reactions (CuAAc) with alkyne-bearing molecules. Additionally, it can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with reagents containing DBCO or BCN groups, making it a versatile tool for click chemistry applications in chemical biology research. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-C7-NH2 is an E3 ligase ligand-linker conjugate featuring Pomalidomide conjugated to a C7 amine linker. This compound serves as a valuable building block for the synthesis of proteolysis targeting chimeras (PROTACs), facilitating targeted protein degradation. Through its targeted interaction with E3 ligases, Pomalidomide-C7-NH2 is instrumental in advancing research in protein regulation and therapeutic development. -
E3 Ligase Ligand-linker Conjugate
Pomalidomide-C6-NHS ester is a synthesized E3 ligase ligand-linker conjugate that features a Pomalidomide-derived cereblon ligand connected through an NHS ester linker. This compound is designed for use in protein degradation studies, allowing for targeted ubiquitination and subsequent proteasomal degradation of specific proteins. Its applications include exploring the mechanisms of protein homeostasis and aiding in the development of novel therapeutics through targeted protein manipulation. -
Ligand for E3 Ligase
Pomalidomide-5-C10-NH2 hydrochloride is a derivative of Pomalidomide that functions as a ligand for the E3 ubiquitin ligase cereblon (CRBN). This compound facilitates the targeted recruitment of CRBN, enabling the formation of PROTAC (proteolysis-targeting chimeras) when linked to a specific protein ligand. Pomalidomide-5-C10-NH2 hydrochloride is suitable for research applications focused on protein degradation pathways and targeted protein modulation. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-4-piperidineacetaldehyde is an E3 ligase ligand-linker conjugate that engages specific E3 ligases for targeted protein degradation. This reagent serves as a critical component in the synthesis of proteolysis-targeting chimera (PROTAC) H122, facilitating the selective elimination of proteins of interest. Its application supports research in protein regulation and dynamics, with implications for therapeutic development in various disease models. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc is an E3 ligase ligand-linker conjugate that harnesses the cereblon-targeting capabilities of thalidomide. This compound serves as a crucial component in the synthesis of PROTACs, specifically facilitating the degradation of BET proteins. Its unique structure enables selective engagement with E3 ligases, making it a valuable tool for researchers investigating targeted protein degradation and related therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
Dione-piperidine-indazol-piperazin-cyclohexyl-NH2 functions as an E3 ligase ligand-linker conjugate, effectively combining a CRBN ligand with a suitable linker. This compound is pivotal for the synthesis of PROTAC MD-4251, facilitating targeted protein degradation in cellular research. Its unique structure allows for efficient engagement with E3 ligases, providing valuable insight into protein modulation and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 45 is an innovative conjugate composed of an E3 ligase ligand and a linker, featuring Thalidomide as a key component. It functions as a Cereblon ligand, facilitating the recruitment of the CRBN protein. This conjugate serves as a critical intermediate in the synthesis of complete PROTAC molecules, thus enabling targeted protein degradation research and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugates
A 410099.1 amide-PEG2-amine-Boc is a functionalized ligand designed for E3 ligase targeting, specifically utilized in PROTAC (Proteolysis Targeting Chimeras) applications. This compound features an IAP ligand combined with a PEG2 linker and a terminal amine, enabling efficient conjugation with target protein ligands. Its design facilitates targeted protein degradation, making it a valuable tool for studying protein function and developing novel therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide 5'-piperazine-4-methylpiperidine functions as an E3 ligase ligand-linker conjugate, facilitating targeted protein degradation. This compound is instrumental in the synthesis of PROTACs, including the development of PROTAC EGFR degrader 13. Its unique structural properties enable the targeted modulation of protein levels, making it valuable for research in therapeutic strategies that leverage the ubiquitin-proteasome system. -
Ligands for E3 Ligase
VH032-C2-NH-Boc is a Boc-modified ligand targeting the von Hippel-Lindau (VHL) E3 ligase, facilitating the recruitment of VHL proteins. Upon exposure to acidic conditions, it readily removes the protecting group, enabling its application in the direct synthesis of PROTAC molecules. This compound serves as an essential intermediate in developing PROTACs that utilize VHL ligands, offering valuable utility in targeted protein degradation research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-amido-C4-Br is a versatile E3 ligase ligand-linker conjugate designed for the synthesis of protein-targeting chimeras, specifically PROTAC degraders such as BSJ-02-162. This compound facilitates targeted protein degradation through the engagement of E3 ligases, thereby modulating protein levels in various biological contexts. It is an essential tool for researchers developing innovative therapies that leverage targeted ubiquitination and degradation pathways. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C12-Br is a synthesized E3 ligase ligand-linker conjugate featuring a Thalidomide-based CRBN ligand. It serves as a crucial component in PROTAC technology, enabling the targeted degradation of proteins. This compound facilitates the assembly of PROTACs, such as EZH2 Degrader-24, and is instrumental in research focused on protein regulation and therapeutic development. -
E3 Ligase Ligand Linker Conjugate
(S,R,S)-AHPC-C7-amine hydrochloride is a novel E3 ligase ligand-linker conjugate that combines a VH032-derived VHL ligand with a C7 linker for targeted protein degradation. Its design facilitates the development of PROTACs targeting estrogen-related receptor α (ERRα), highlighting its utility in research on protein modulation and degradation pathways. This compound serves as a valuable tool in the study of E3 ligase-mediated degradation mechanisms and therapeutic applications in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-C13-piperazine-Boc is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC degraders, specifically NC-R17. This compound facilitates targeted protein degradation by connecting a ligand for E3 ligases to a protein of interest. Its application in PROTAC technology enables the modulation of protein levels, making it a valuable tool for researchers studying protein regulation and therapeutic degradation strategies. -
E3 Ligase Ligand-Linker Conjugates
(S,S,S)-VH032-cyclopropane-F-C4-aldehyde is an E3 ligase ligand-linker conjugate designed for use in the synthesis of PROTAC compounds, specifically cis-VZ185. This reagent facilitates targeted protein degradation by engaging with the ubiquitin-proteasome system, making it a valuable tool for researchers investigating protein modulation and degradation pathways. Its unique structure allows for precise conjugation in drug discovery applications focused on cancer and other diseases influenced by protein dysregulation. -
E3 Ligase Ligand-linker Conjugatecan
Boc-4-(3-oxobutyl)piperidine-(S,R,S)-AHPC is a ligand-linker conjugate designed for targeting E3 ligases in protein degradation applications. This compound facilitates the development of proteolysis targeting chimeras (PROTACs), specifically in the synthesis of BRD2 BD1 Degrader-1. It plays a crucial role in selective protein degradation research and expanding therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 176 is designed to bind specifically to E3 ligases, facilitating targeted protein degradation through the ubiquitin-proteasome system. This conjugate enables the synthesis of BMS-986458, allowing for further exploration of E3 ligase modulation in various biological contexts. It is essential for studies focused on protein homeostasis and the therapeutic potential of targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugate
Deoxy-thalidomide-C4-NH2 is a ligand-linker conjugate targeting the E3 ligase Cereblon (CRBN). This compound facilitates the development of Proteolysis Targeting Chimeras (PROTACs), specifically for synthesizing BRD4 degraders. Its unique structure supports targeted protein degradation, making it a valuable tool for research in cellular protein regulation and therapeutics. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-S-C6-acid is a synthetic E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a C6 linker. This compound facilitates the development of PROTACs, specifically designed for targeted protein degradation applications, including the synthesis of the PROTAC Cas9 Degrader-1. Its ability to engage with E3 ligases makes it a valuable tool in biochemistry and molecular biology research focused on therapeutic interventions through targeted protein modulation. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 174 is a specialized reagent designed to target E3 ligases through a ligand-linker conjugate. This compound facilitates the synthesis of the potent compound TYD-68, enabling researchers to explore the role of E3 ligases in ubiquitination processes. Its application in chemical biology can aid in the development of targeted therapies and the study of protein degradation pathways. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-Pip-butyn is an E3 ligase ligand-linker conjugate derived from Lenalidomide. It effectively recruits the CRBN protein, facilitating targeted protein degradation through the formation of proteolysis-targeting chimeras (PROTACs). This reagent is particularly useful for creating PROTACs like the STAT3 degrader SD-436, enabling studies on protein regulation and degradation pathways in cellular models. -
BRD4 PROTAC
Lenalidomide-CO-C7-NH2 is a CRBN-dependent intermediate designed as a BRD4-targeting PROTAC degrader. This compound facilitates the selective degradation of the oncoprotein BRD4, leading to decreased cancer cell proliferation, cell cycle arrest, and enhanced apoptosis. It demonstrates noteworthy anti-tumor efficacy in xenograft models, making Lenalidomide-CO-C7-NH2 a valuable tool for investigating mechanisms in acute myeloid leukemia research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG3-COOH is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation via the cereblon pathway. This compound integrates a Thalidomide-derived cereblon ligand with a PEG3 linker, optimizing its application in PROTAC (Proteolysis Targeting Chimera) technology. Its unique structure enhances cellular interaction and degradation of specific target proteins, making it a valuable tool for researchers investigating protein regulation and therapeutic development. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 218 is designed as a specific ligand-linker construct targeting E3 ligases. This compound plays a crucial role in the development of PROTACs, specifically in the synthesis of STAT6 degrader-2. Researchers can utilize this conjugate to facilitate targeted protein degradation, enhancing studies in protein homeostasis and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-4-OH-C11-OH is an E3 ligase ligand-linker conjugate designed to recruit the cereblon (CRBN) protein. This compound serves as a crucial intermediate in the synthesis of proteolysis-targeting chimeras (PROTACs), including various targeted degraders. Its application in the development of PROTACs facilitates targeted protein degradation, providing insights into cellular mechanisms and therapeutic opportunities in various diseases. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 170 is a specialized conjugate that facilitates the synthesis of PROTACs by incorporating an E3 ligase ligand with a linker. This compound demonstrates potent anti-proliferative activity in non-Hodgkin's lymphoma cell line SU-DHL-4, exhibiting an IC50 value of less than 0.2 μM. It is an essential tool for researchers investigating targeted protein degradation pathways and their implications in cancer therapeutics. -
Ligands for E3 Ligase
VH032-C3-Boc is a Boc-modified derivative of VH032, functioning as a ligand for the E3 ligase von Hippel-Lindau (VHL). Under acidic conditions, VH032-C3-Boc enables the removal of the protective group, facilitating direct utilization in the synthesis of proteolysis-targeting chimeras (PROTACs). This compound serves as an essential intermediate for developing VHL-based PROTACs, contributing to advancements in targeted protein degradation research. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-Glycolic acid is an E3 ligase ligand-linker conjugate designed for use in PROTAC technology. This compound facilitates the targeted degradation of specific proteins, most notably as a component in the FLT3 degrader LWY713. Its application in research focuses on understanding protein homeostasis and the modulation of oncogenic pathways, making it a valuable tool for drug development in cancer therapeutics. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-alkyne-C4-NHBoc is an E3 Ligase Ligand-Linker Conjugate designed for targeted protein degradation applications. This compound facilitates the synthesis of PROTAC JAK1 degrader 1, enabling the selective degradation of the JAK1 protein. Its utility in research includes studying protein turnover and the therapeutic potential of targeted protein degradation in various diseases. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C2-piperazine-Boc is an E3 ligase ligand-linker conjugate designed for the synthesis of Proteolysis Targeting Chimeras (PROTACs). This compound facilitates targeted degradation of proteins, enabling researchers to manipulate cellular pathways and study protein function. It serves as a key component in the development of PROTACs, such as PROTAC BET Degrader-15, offering significant potential for applications in therapeutic research and drug discovery. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 115 is a potent E3 ubiquitin ligase ligand combined with a linker, designed for the development of targeted protein degradation strategies. This compound serves as a crucial component in synthesizing PROTAC SMARCA2/4-degrader-27, enabling researchers to investigate the modulation of specific protein levels through ubiquitin-proteasome pathway engagement. Its application in chemical biology provides a valuable tool for studying protein function and regulation in various cellular contexts. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 156 functions as a CRBN E3 ligase ligand-linker conjugate. It serves as a key component in the development of PROTAC (Proteolysis Targeting Chimera) molecules, enabling targeted protein degradation. This compound is particularly relevant for research applications focusing on modulating protein levels in cellular systems, including the synthesis of XPO1 degrader-1. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-amino-PEG4-C4-Cl is an E3 ligase ligand-linker conjugate that features a Pomalidomide-based cereblon (CRBN) ligand. This compound facilitates the development of PROTACs, which are designed to selectively degrade target proteins via the ubiquitin-proteasome pathway. Its chemical structure, incorporating an amino-PEG4 linker, enhances its utility in targeted protein degradation research and other related applications in chemical biology. -
Ligands for E3 Ligase
β-Naphthoflavone-CH2-OH is a selective ligand for the arylhydrocarbon receptor (AhR) E3 ligase. This compound serves as a critical component in the design of targeted protein degradation strategies, such as PROTACs and SNIPERs, by linking to specific protein ligands to facilitate the recruitment of the AhR E3 ligase complex. Its ability to induce ubiquitination-mediated degradation of oncoproteins makes it a valuable tool in cancer research and drug discovery. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-amido-PEG2-NH2 is a synthesized E3 ligase ligand-linker conjugate that utilizes a thalidomide-derived cereblon ligand. This compound features a PEG2 linker, facilitating the development of PROTACs for targeted protein degradation. It is valuable in research applications focusing on E3 ligase modulation and therapeutic interventions in cellular protein regulation. -
E3 Ligase Ligand-Linker Conjugate
Succinic acid-Pomalidomide is an E3 ligase ligand-linker conjugate designed for use in the synthesis of PROTACs (proteolysis-targeting chimeras). By leveraging the interaction with E3 ligases, this compound facilitates targeted protein degradation, which is a key process in drug discovery and development. Its application is beneficial for researchers focusing on selective modulation of protein levels for therapeutic purposes. -
E3 Ligase Ligand-Linker Conjugate
CRBN ligand-8-O-C6-NH2 is an E3 ligase ligand-linker conjugate that targets the cereblon (CRBN) E3 ubiquitin ligase, facilitating targeted protein degradation. This compound serves as a critical component in the synthesis of PROTAC ERα Degrader-11, thus aiding in the study of estrogen receptor-alpha (ERα) modulation and its associated cellular pathways. Researchers can utilize CRBN ligand-8-O-C6-NH2 for advancing the development of targeted therapeutic strategies in cancer and other diseases influenced by ERα signaling. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-bis-NH2-C1-PEG3 is a synthesized E3 ligase ligand-linker conjugate designed for the development of PROTACs. This compound facilitates targeted protein degradation through the recruitment of E3 ligases, enabling the selective eradication of specific proteins within cellular systems. Its applications extend to various research areas, including cancer biology and drug discovery, providing a valuable tool for investigating protein regulation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-CO-PEG-C2-iodine is a specifically designed E3 ligase ligand-linker conjugate that targets the VHL E3 ubiquitin ligase. This compound facilitates the synthesis of PROTACs, which are engineered to induce targeted protein degradation. It is particularly useful in the development of PROTACs like the FAK degrader 1, enabling researchers to investigate the therapeutic potential of targeted protein degradation in various biological contexts. -
Ligands for E3 Ligase
VH 032 amide-PEG6-amine hydrochloride is a functionalized ligand for the von Hippel-Lindau (VHL) E3 ligase, specifically designed for PROTAC (Proteolysis Targeting Chimera) development. This compound features an E3 ligase ligand conjugated to a PEG6 moiety, facilitating the incorporation of terminal amines for coupling with target protein ligands. VH 032 amide-PEG6-amine hydrochloride is essential for advancing research in targeted protein degradation and drug development strategies. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 178 is a chemical entity designed to engage with E3 ligases, facilitating targeted protein degradation. This conjugate serves as a versatile tool for synthesizing downstream compounds, notably MS2133. Its application supports research in protein homeostasis and therapeutic development, particularly in the realm of targeted cancer therapies and cellular signaling modulation. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-OCH2-amide-PEG2-C2-Boc is a ligand-linker conjugate designed for E3 ligase targeting, specifically interacting with the cereblon (CRBN) E3 ubiquitin ligase. This compound facilitates the development of PROTACs, including SARS-CoV-2 Degrader-1, making it valuable for research in targeted protein degradation and therapeutic applications against viral infections. Its structural components ensure efficient conjugation for effective modulation of protein levels within cellular systems. -
E3 Ligase Ligand-Linker Conjugate
N-Me-Thalidomide-NH-C6-NH2 is an E3 ligase ligand-linker conjugate designed for the targeted modulation of protein degradation pathways. This compound has demonstrated key biological activity in facilitating the development of novel anti-inflammatory agents, such as Anti-inflammatory agent 70. It serves as an important tool for researchers investigating targeted protein degradation and its therapeutic applications in various inflammatory diseases.
-
E3 Ligase Ligand-Linker Conjugate
(R,S,S)-VH032-Me-glycine is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound enables the synthesis of novel bifunctional molecules, such as XF067-68, which can facilitate selective modulation of protein stability in biological systems. Its utility in creating targeted therapeutic agents makes it valuable for research in drug development and cellular regulation. -
IAP Ligand
A 410099.1, amine-Boc is a functionalized inhibitor of apoptosis protein (IAP) ligand that serves as a valuable building block for synthesizing proteolysis-targeting chimeras (PROTACs). This compound is particularly useful in the development of PROTACs that target Bruton's tyrosine kinase (BTK), showing promise for applications in cancer research and therapeutic development. Its ability to help modulate protein degradation makes it a potent tool in the exploration of novel treatment strategies. -
E3 Ligase Ligand-Linker Conjugate
DHFR-IN-5-amino-PEG3-C2-azido is an E3 ligase ligand-linker conjugate designed for the synthesis of BION106, a potent DHFR-TS PROTAC degrader. This compound exhibits significant anti-malarial activity, making it a valuable tool in research focused on targeted protein degradation and parasitic diseases. Its unique structure facilitates the development of innovative therapeutic approaches in the field of drug discovery and development. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-C2-NH2 is an E3 ligase ligand-linker conjugate that incorporates the VH032-derived VHL ligand, designed for applications in targeted protein degradation via PROTAC technology. This compound facilitates the recruitment of E3 ligases to target proteins, enabling efficient ubiquitination and subsequent proteasomal degradation. Its use in research can enhance the understanding of protein dynamics and assist in the development of therapeutics aimed at regulating protein levels in various disease contexts. -
E3 ligase ligand-linker conjugate
E3 Ligase Ligand-linker Conjugate 215 is designed as a specific E3 ligase ligand-linker conjugate. This compound facilitates the synthesis of STAT3 PROTAC Degrader S3D5, enabling selective degradation of the STAT3 protein. It serves as a valuable tool in research focused on targeted protein degradation and the modulation of cellular signaling pathways related to oncogenesis and inflammation. -
Vhl Ligand-Linker Conjugate
(S,R,S)-AHPC-C3-COOH is a carboxylic acid derivative targeting the VHL E3 ubiquitin ligase, functioning as a ligand-linker conjugate. This compound is instrumental in the synthesis of PROTACs (Proteolysis Targeting Chimeras), facilitating targeted protein degradation for potential therapeutic applications. Its structural properties make it a valuable tool in chemical biology for exploring ubiquitin-mediated proteolysis and developing innovative strategies in drug discovery.
